The promoter of the cystic fibrosis transmembrane conductance regulator gene CFTR is tightly controlled by regulators including CCAAT/enhancer binding proteins (C/EBPs). We previously reported that the transcription factors YY1 and USF2 affect CFTR expression. We can now demonstrate that C/EBPb, a member of the CCAAT family, binds to the CFTR promoter and contributes to its transcriptional activity. Our data reveal that C/EBPb cooperates with USF2 and acts antagonistically to YY1 in the control of CFTR expression. Interestingly, YY1, a strong repressor, fails to repress the CFTR activation induced by USF2 through DNA binding competition. Collectively, the data strongly suggest a model by which USF2 functionally interacts with YY1 blocking its inhibitory activity, in favour of C/EBPb transactivation. Further investigation into the interactions between these three proteins revealed that phosphorylation of C/EBPb influences the DNA occupancy of YY1 and favours the interaction between USF2 and YY1. This phosphorylation process has several implications in the CFTR transcriptional process, thus evoking an additional layer of complexity to the mechanisms influencing CFTR gene regulation. 
Introduction
The CCAAT/enhancer binding proteins (C/EBPs) encompass a family of structurally similar yet functionally and genetically distinct transcription factors with functional roles in a number of physiological activities [1] . In mammals there are six members including C/EBPa, C/EBPb, C/EBPd and C/EBPc [2] . C/EBP expression has been linked to development, cellular differentiation and regulation of tissue specific gene expression [2, 3] . The C/ EBPs are essential in a variety of tissues such as the lung where spatial and temporal regulation of CFTR expression is functional in maturation [3, 4] . Previous findings of several independent investigators demonstrated C/EBPd as a positive regulator acting on the CFTR promoter [5, 6, 7] . In addition, Nuthall et al. [8] demonstrated that C/EBPb binds to a DNase I-hypersensitive site, only present in tissue expressing CFTR. Through the functional analysis of sequence variations within the CFTR promoter, our laboratory identified other trans-acting proteins including YY1 and USF2 with repressor and activator activities, respectively [9, 10, 11] . However, the mechanistic basis of these activities has not been fully elucidated. Review of the CFTR gene sequence between 2226 and +135 bp upstream of the major transcription initiation site [12] , indicates that this region includes a C/EBPb binding element that immediately flanks YY1 and USF binding motifs.
Through the differential usage of AUG codons within the same transcript, C/EBPb encodes the different polypeptide isoforms liver-enriched activatory protein (LAP) [13] and liver-enriched inhibitory protein (LIP) [14, 15] . LAP contains both transcription activating and bZIP domains. LIP has only the bZip domain but can dimerize and bind DNA and acts as a transcriptional repressor [14] .
Determining the function of C/EBP transcription factors may be achieved in part through protein-protein interactions [1] . Recent findings indicate that interaction of C/EBPs with non-C/ EBP transcription factors may be relevant. Indeed Crawford et al. [16] reported that C/EBPc regulates gene expression in human bronchial epithelial cells and this regulation is modified in part by interaction with YY1. In addition, C/EBPd was reported to compete with USF for overlapping sites in the negative regulatory region of the HIV-1 long terminal repeat gene HIV-1 LTR [17] . C/EBPb has also been shown to control cell-type-specific activity of viral gene through formation of a complex with YY1 [18] . The authors also reported that the YY1 activity is dependent on its functional interaction with an adjacent sequence [18] .
Alternatively, multiple phosphorylation events have been shown to be critical in the regulation of members of the C/EBP family [2] . Human C/EBPb has several known phosphorylation sites which are important for its intracellular localization and transcriptional activity [13, 19, 20, 21] . Indeed, C/EBPb phosphorylation may lead to enhanced nuclear translocation [19] , inactivation of inhibitory activities [22] or an increase in the potency of its transcriptional activation domain [20, 21] .
In this report, we investigate the role of C/EBPb in the control of CFTR gene expression and attempt to unravel the molecular mechanisms involved. Considering that C/EBPb phosphorylation has already been demonstrated to modulate its DNA binding capacity and the transcriptional activities of other genes [19] , we wished to evaluate the implication of this posttranslational modification in CFTR transcription.
Materials and Methods

DNA Plasmids and Constructions
For transfection assays the following expression vectors were used: pBS-C/EBPb (S. McKnight, UT Southwestern Medical Centre), pCMV-LIP and pCMV-LAP (P. Gos, Département de Biologie Moléculaire), pCMV-Flag-A-C/EBP (V. Rishi, Laboratory of Metabolism, NCI, NIH), pCDNA3-hLAP-T235A (J. Scharwtz, Department of Physiology, University of Michigan), pCR3-USF2 (B. Viollet, Department of Endocrinology, Metabolism and Cancer) and pCDNA3-YY1 (E. Bonnefoy, Laboratoire de Régulation de la Transcription et Maladies Génétiques).
To study the importance of the C/EBPb cis-acting elements, mutations within the core CAAT were generated from the WTpGL3 plasmid using an oligonucleotide-directed mutagenesis system (QuickChange II TM Site-Directed Mutagenesis Kit, Stratagene) according to the manufacturer's instructions. Mutagenesis primers are available on demand. The presence of mutations and the sequences fidelity were verified by dideoxynucleotide sequencing.
Transient Transfections
Human bronchial epithelial cells, Beas2B, expressing endogenous CFTR, were transiently transfected as previously described [11] except for some minor modifications. They were seeded in 96-wells and transfected using Fugene6H reagent (Roche diagnostics) with 0.072 mg of reporter CFTR promoter plasmid, 0.008 mg of internal control pRL-SV40 containing Renilla luciferase and 0.004 to 0.08 mg of each expression vector. Transfections with siRNA were performed using Fugene6H reagent (Roche diagnostics) with 1.2 ml of either control (non-targeting siRNA: sc-37007 from Santa Cruz, Clinisciences) or C/EBPb siRNA (sc-44251, Santa Cruz, Clinisciences) for three wells. When indicated, medium containing sodium fluoride (NAF, a Ser/thr phosphatase inhibitor) was added to cells. All luciferase activities represent at least three independent experiments with each construct tested in triplicate per experiment.
Western Blot Analysis and Immunoprecipitation Assays
Protein extracts, resuspended directly in 1X Laemmli sample buffer, were resolved on a 10% SDS-polyacrylamide gel as previously described [9] and transferred to an Immobilon PVDF membrane (WestranH Clear Signal, Whatman). The membranes were incubated with the indicated antibodies in 5% skimmed milk overnight at 4uC: anti-C/EBPb (sc-150X, 1:2500 dilution), anti-USF2 (sc-862X, 1:5000 dilution) or anti-YY1 (sc-1703X, 1:2500 dilution) purchased from Santa Cruz, Clinisciences; anti-phospho-C/EBPb (Thr235) (1:1000 dilution) from Cell Signaling Technology; anti-CFTR (clone 24-1, dilution of 1:200) from R&D Systems Europe; and anti-Flag (dilution of 1:500) and anti-laminA/C (dilution of 1:250) from Sigma-Aldrich Corporation. The membranes were then washed and incubated with an appropriate horseradish peroxidase (HRP) conjugated secondary antibody (sc-2004 or sc-2005, SantaCruz) at 1:40000 in PBS-5% milk. The level of lamin A/C was assayed for internal control of protein loading. For immunoprecipitation assays, cells were resuspended in RIPA buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS and 5mM EDTA, protease inhibitors cocktail) before being immunoprecipitated using ExactaCruz F kits (sc-45043, Santa Cruz, Clinisciences). Immunoprecipitations were performed using 3 mg of specific (as indicated) or non-specific (anti-HA 12CA5, Roche Applied Science) antibodies. Extensively washed immunoprecipitates were then separated in SDS-PAGE gel and analyzed by western blotting.
Reverse-transcriptase and Quantitative PCR Total RNAs were extracted using the RNeasy Plus Mini kit (Qiagen SA). Reverse transcription was performed as previously described [9] , and cDNA were amplified with CFTR primers (Table1) using the LightCyclerH 480 Real-Time PCR System (Roche Applied Science) as recommended by the manufacturers. The endogenous levels of either CFTR mRNA or C/EBPb mRNA were normalized to the expression of endogenous GAPDH mRNA, used as an internal control (primer listed in table 1). All PCR reactions were performed in triplicate in at least three independent experiments. Formaldehyde Cross-linking and Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed using the Chromatin Immunoprecipitation Assay Kit (Upstate) following Upstate ChIP protocols, with minor modifications. As indicated, Beas2B cells were transfected with either expression vectors or C/EBPb siRNA and/ or treated with 10 mM of NAF for 4 hours. Prior to harvesting, cells were incubated with 5 mM of DTBP for 30 min at RT, followed by treatment with formaldehyde 1% for 5 min. For each immunoprecipitation, 2610 6 cell equivalents of lysate were used. Following shearing of the crosslinked chromatin by sonication, chromatin was incubated at 4uC on a rotating stand overnight with either 3 mg of anti-C/EBPb, anti-USF2, anti-YY1 or nonspecific antibodies (anti-HA). ChIP samples (immunoprecipitated or input DNA) were analyzed by either classical PCR or quantitative PCR. For both analyses, primers used for CFTR promoter amplification are reported in Table 1 . As a negative control, PCR analysis was carried out using primers from a region of the human CFTR gene which lacks both C/EBPb and YY1 motifs: 59-TGTGGGGAGGGAAATAGATG-39 and 59-GCA-GAGTTTGCAGTGAGCTG-39. The fold change in the specific binding was normalized to mock input values. For quantitative ChIP, all PCR reactions were performed in triplicate in a final volume of 10 ml containing 2 ml of sample, 5 mM of each primer (Table 1) , 0.1 ml of Universal Probe ?27 (Roche Applied Science) and 5 ml of LightCyclerH 480 probes mastermix using the LightCyclerH 480 Real-Time PCR System (Roche Applied Science). Experiments were repeated at least three times, averaged and expressed relative to the input signal and to the negative control (non-specific, NS, antibody).
Nuclear Extract and Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts were prepared from Beas2B cells as previously described [10] . Double-stranded oligonucleotides containing each wild-type or degenerated C/EBPb motif (Table 1) identified within the minimal promoter were labelled and incubated with 10 mg of nuclear proteins in 10 ml of binding buffer (2x) containing 0.5 mg polydIdC at RT for 15 min. As indicated, purified antibodies (anti-C/EBPb, anti-YY1 or anti-HA) were incubated with nuclear extracts before the addition of labelled probes. Purified C/EBPb proteins were produced using TNT Quick Coupled Transcription/Translation (Promega).
Statistical Analyses
Transfection data are expressed as the mean 6 S.E. Paired comparisons were made using student's t-test. Data were considered statistically significant at p,0.05. All graphical data and statistical analyses were generated with GraphPAD Prism software (Version 3.0). Densitometric analyses were performed using computerized densitometry and Quantity OneH software (Biorad). Densitometric values for both protein band (immunoblot) and promoter CFTR amplicons (ChIP) were determined in areas of equal size and were reported in normalized arbitrary units relative to either expression of LaminA/C protein or input (nonimmunoprecipitated chromatin), respectively.
Results
C/EBPb Binds to and Activates the CFTR Promoter
To evaluate whether C/EBPb binds to the minimal CFTR promoter, we performed chromatin immunoprecipitation (ChIP) assays using crosslinked protein-DNA complexes prepared from Beas2B cells. The immunoprecipitates obtained with antibodies directed against the C-terminus of C/EBPb and a non-specific control protein were used as templates to amplify a 360 bp DNA fragment corresponding to the minimal CFTR promoter. Quantitative PCR (qPCR) amplifications of DNA immunoprecipitated by anti-C/EBPb revealed that endogenous C/EBPb binds to the CFTR promoter in Beas2B cells ( Figure 1A ). This binding was increased when C/EBPb expression ( Figure 1A ) was enforced after normalization to input values. The control antibody was unable to precipitate any DNA target ( Figure 1A ). As a negative control for the C/EBPb antibody, ChIP analysis was performed on another region of the CFTR gene devoid of any C/EBPb binding motif (data not shown).
To measure the functional contribution of C/EBPb towards promoter activity, reporter gene assays were performed with a CFTR promoter fused to a luciferase-coding cDNA in Beas2B cells. Overexpression of the C/EBPb-LAP construct resulted in a 3.7 fold increase promoter activity ( Figure 1B , upper panel). As expected, the truncated C/EBPb-LIP form did not activate the CFTR promoter and the observed decrease in promoter activity supported a dominant negative influence of the LIP isoform as previously reported [2] . The functional role of C/EBPb was corroborated by the almost complete abolishment of CFTR gene promoter activation following transient co-transfections of the dominant-negative (A-C/EBP), reported to dimerize with C/ EBPb thus blocking its DNA binding ( Figure 1B Figure 1C , lower panel) and significantly reduced the CFTR promoter activity ( Figure 1C , upper panel), confirming the activator role of C/EBPb. As a control, the cells were transfected with a ''non-silencing'' siRNA predicted to not target any gene. To ensure that the C/EBPb influences endogenous CFTR mRNA, RT-qPCR assays were performed. As observed in Figure 1D , C/EBPb induced an increase in the CFTR mRNA level in Beas2B cell lines; this positive effect on transcription was confirmed by using C/EBPb-specific siRNA. Collectively, these findings firmly support an activating effect of C/EBPb on the CFTR promoter.
Mutation of a C/EBPb Binding Motif Reduces the CFTR Transcriptional Activity
In silico analyses (TFsearch http://www.cbrc.jp/research/db/ TFSEARCH.html, and Consite software http://asp.ii.uib. no:8090/cgi-bin/CONSITE/consite/) were performed to identify putative binding sites for the transcription factor C/EBPb. The results indicated that the CFTR minimal promoter region contains different binding motifs for C/EBPb as depicted in Figure 2A . To address whether C/EBPb influences the CFTR promoter directly or exerts its effects through an indirect activation of other proteins that do directly influence CFTR, mutagenesis reactions of the core sequence (TTNNNCAATNNN) of each C/EBPb binding site in the reporter construct were performed. As shown in Figure 2B , the construction containing a nucleotide substitution (b3M) within the consensus core of the C/EBPb motif located at the position 2111/2100, named C/EBPb3, induced a significant 80% reduction in the transcriptional activity compared to the wild-type construct. In addition, the binding availability of each C/EBPb motif was evaluated using EMSA assays. Incubation of short, radiolabeled oligonucleotide probes containing each wild-type (b1WT to b5WT) or degenerated (b1M to b5M) C/EBPb site with nuclear extracts from Beas2B cells, resulted in different complexes that appeared altered in the mutated compared to in the wild-type context ( Figure 2C ). Very few complexes were formed and only with the b3WT probes. In addition the Beas2B-nuclear extracts seemed to be only slightly affected by incorporating cold C/EBP consensus sequence. Since the disruption of the C/EBPb motif did not completely abolish CFTR transcription, this would suggest the implication of additional transcription factors.
C/EBPb Cooperates with USF2 to Activate the CFTR Promoter
Based on the knowledge that C/EBPb heterodimerization is important for its DNA binding [23] , we sought to investigate the relationship between C/EBPb and the other transcription factors that we previously characterised as binding to and regulating CFTR in proximity to the C/EBPb3 motif. In a first set of experiments, transient co-transfection assays were carried out to evaluate the putative cooperative role of C/EBPb with USF2, Sp1 and SRF positive factors (binding motifs depicted on Figure 3A ). The data presented in Figure 3B (left panel) demonstrate that overexpression of USF2 up-regulated the transactivation induced by the C/EBP-LAP construct in human lung cells. However, no cooperation between C/EBPb and either SRF or Sp1 was apparent (data not shown). All results were confirmed at the mRNA level by qPCR, all be it the cooperation between C/EBPb and USF2a was weaker than that observed by the gene reporter assays ( Figure 3B, right panel) . Given the functional relationship between C/EBPb and USF proteins, we carried out coimmunoprecipitation experiments. The results of immunoblots revealed that C/EBPb and USF2 proteins bind to each other in Beas2B cells ( Figure 3C ). Taken together these observations support the notion that the CFTR promoter is activated by the concerted action of C/EBPb and USF transcription factors.
Functional Antagonism between C/EBPb and YY1 Through DNA-binding Competition Since YY1 has been previously shown to negatively regulate the CFTR promoter [9] , it was logical therefore to presume that C/ EBPb and YY1 be putative functional competitors for CFTR promoter activity. This hypothesis was investigated by transient co-transfections with both C/EBPb and YY1 expression vectors. As observed in Figure 4A (left panel), the stimulating effect of C/ EBPb progressively decreased on addition of increasing quantities of YY1 plasmid. To determine the potential displacement of YY1 binding by C/EBPb binding, ChIP experiments were conducted using extracts prepared from Beas2B cells transfected with either C/EBPb expression vector or its respective siRNA. As a negative control for YY1 antibody, ChIP analysis from another region of the CFTR gene devoid of any YY1 motif was performed (denoted negative control). C/EBPb overexpression significantly reduced the YY1 DNA binding activity ( Figure 4B, left panel) . Interestingly, the binding of YY1 to its cognate site was restored by transfection of the C/EBPb siRNA. ChIP-qPCR confirmed that overexpression of C/EBPb significantly decreases the YY1 binding on the CFTR minimal promoter ( Figure 4B, right panel) . Both YY1 and C/EBPb-specific siRNA overexpression also indicated the antagonising effects of C/EBPb and YY1. To determine whether the interaction of these two factors with their target DNA containing the C/EBPb3 motif and a YY1 binding site ( Figure 4C , right panel) was either mutually inclusive or exclusive, EMSAs were conducted. As shown in Figure 4C (left panel), the YY1-binding complex was altered by increasing the C/EBPb binding activity, suggesting their mutually exclusive binding. These results demonstrate a functional antagonism between C/EBPb and YY1 through DNA-binding competition.
C/EBPb Transactivation is in Part Due to Interaction between USF2 and YY1
Considering the observed cooperation between C/EBPb and USF2 and the antagonism between C/EBPb and YY1, we wondered whether YY1 had any effect on the cooperativity between C/EBPb and USF2. We firstly tested whether enforced YY1 expression antagonizes USF2 transactivation. Surprisingly, YY1 overexpression had no considerable effect on the CFTR promoter transactivation induced by USF overexpression ( Figure 5A, left panel) . To evaluate the effect of a combined YY1 and USF2 overexpression on the endogenous CFTR mRNA level, RT-qPCR assays were conducted. The results confirm the data obtained by gene reporter assays ( Figure 5A, right panel) . To explain the functional cooperation between C/EBPb and USF2, we next explored whether USF might block the action of YY1 through USF2/YY1 interaction. Co-immunoprecitation experiments revealed a physical interaction between YY1 and USF2 in Beas2B cells ( Figure 5B ). We then tested whether enforced USF2 expression might decrease the YY1 recruitment onto the CFTR promoter. As presented in Figure 5C (left panel) USF2 overexpression reduced YY1 binding to the CFTR promoter, as shown by ChIP analyses. To confirm these data, Chip-qPCR assays were also conducted showing that USF2 overexpression significantly decreased the YY1-binding capacity by 50% ( Figure 5C , right panel). Taken together, these data strongly suggest that USF2 and YY1 interact in vivo and this interaction seems to prevent the YY1 DNA occupancy.
Phosphorylation of C/EBPb is Associated with CFTR Transactivation
Since the acquisition of transcriptional activity for various transcription factors including C/EBPb requires their phosphorylation [24] , we first wondered whether treatment with phosphatase inhibitors might influence the CFTR activity. We evaluated the effect of either sodium fluoride (NAF, a serine/threonine inhibitor) or vanadate (Vana, a tyrosine phosphatase inhibitor) treatment at different concentrations on the CFTR transcription. While vanadate did not modify the CFTR expression level (data not shown), treatment with either 5 mM or 10 mM NAF significantly increased the luciferase activity to over 1.5-and 2.5-fold, respectively ( Figure 6A , left panel). Western blotting experiments using an anti-CFTR antibody demonstrated that endogenous CFTR expression correlated well with the observed luciferase activity. Densitometric analysis (denoted DA) was performed to evaluate the protein expression level and the values are indicated under the immunoblots. RT-qPCR assays confirmed the results showing an increase of 2-or 3-fold in the CFTR mRNA different forms of C/EBPb (left panel) and the C/EBPb-specific siRNA (right panel). The mRNA expression level following transfection of either an empty vector or a control siRNA was then set as 1. The asterisk reflects the statistical significance set at P,0.05. doi:10.1371/journal.pone.0060211.g001 level following 5 mM or 10 mM NAF treatment, respectively ( Figure 6A, right panel) . RT-qPCR assays were also performed to assess the effect of NAF treatment on the C/EBPb transcripts. The results show that incubation of either 5 mM or 10 mM NAF did not affect the endogenous C/EBPb mRNA level ( Figure 6A , right panel).
We next examined the role of phosphatase inhibitor on the C/ EBPb-mediated CFTR transactivation. As observed in Figure 5B , at 10 mM NAF significantly promoted CFTR activation induced by over-expression of C/EBPb in Beas2B cells. In contrast, NAF treatment did not modify USF2 transactivation on the CFTR promoter (data not shown). Western blot assays were carried out to assess the protein expression levels under the indicated treatments. Immunoblotting with a specific anti-phospho-C/EBPb antibody showed that treatment with NAF increased the level of phosphorylated C/EBPb ( Figure 6B, upper panel, left panel) . Interestingly, immunoblotting also revealed that the level of endogenous CFTR protein increased after C/EBPb overexpression, reaching its maximum level upon NAF incubation ( Figure 6B , middle and left panel). These data were validated by using dominant negative Figure 2 . The C/EBPb motif located at position 2111/2100 is important for CFTR transcriptional activity. (A) Sequence of the CFTR minimal promoter containing five binding sites for the C/EBPb transcription factor. The C/EBPb motifs are underlined. The major transcriptional start site is indicated by +1. (B) Basal transcriptional activity of wild-type or degenerated C/EBPb motifs of the CFTR promoter. On the left is a schematic scaled representation of the full-length pGL3 and degenerated binding motifs for the C/EBPb transcription factor. Luciferase activity obtained with the WT-pGL3 luciferase construct was defined as 100%, and relative activities from mutant constructs are expressed as a percentage of this value. *P,0.05. (C) EMSA analysis with nuclear extracts from C/EBPb protein-enriched Beas2B cells using wild-type or mutated labelled oligonucleotide probes (sequences listed in Table 1 ). Competitors (DC, Degenerated Competitors or specific competitors of C/EBPb) or antibodies (NS, Non Specific or directed against C/EBPb) were also used. Arrow corresponds to complexes containing C/EBPb. doi:10.1371/journal.pone.0060211.g002 form of C/EBP (A-C/EBP) showing that no CFTR expression was observed after A-C/EBP overexpression following NAF treatment (data not shown). These results indicate that NAF-induced C/ EBPb phosphorylation is involved in CFTR activation. To assess whether the increased CFTR expression could be an indirect consequence of the general effects of NAF on promoter efficiency, we performed transfection assays using mutant hLAPT235A vector (denoted T235A), in which the conserved Thr235 is mutated to Ala. As presented in Figure 6B (upper and right panel) , the overexpression of the LAP expression vector containing a mutation of the Thr235 induced only a two-fold increase in the luciferase transcription. Although western blot assays revealed an increase in C/EBPb expression level after either C/EBPb or T235A overexpression, the anti-phospho-C/EBPb antibody was unable to detect mutated T235A highlighting the specificity of the antibody ( Figure 6B, middle and right panel) . RT-qPCR assays were then performed to evaluate the effect of C/EBPb phosphorylation on the mRNA level of endogenous CFTR. The results confirmed the data obtained by gene reporter assays ( Figure 6B , lower panels). Interestingly, overexpression of hLAPT235A vector induced a decrease in CFTR mRNA level. These results indicate for the first time that C/EBPb phosphorylation is involved in CFTR transcriptional activation.
Phosphorylation Affects Both C/EBPb and YY1 DNA Binding Abilities and Favours YY1/USF2 Interaction
Considering that C/EBPb appears to undergo phosphorylation in correlation with the acquisition of DNA-binding activity [2] , we used ChIP assays to address the C/EBPb activity in terms of its phosphorylation status. NAF induced-phosphorylated C/EBPb was associated with both an increased C/EBPb DNA binding activity and a decrease in YY1 DNA binding in vivo ( Figure 7A , left and right panels, respectively). To validate these results, we evaluated the C/EBPb ( Figure 7A , left panel) and YY1 ( Figure 7A , right panel) occupancies on the CFTR target sequence after overexpression of the LAPT235A mutant (denoted T235A). As depicted in Figure 7A (upper panels), LAPT235A could bind to the CFTR promoter but the level of binding was much lower by comparison with the phosphorylated C/EBPb. These results were confirmed by ChIP-qPCR showing that LAPT235A overexpression induced a considerable decrease in C/EBPb binding (nearly 3-fold) that was associated with a modest increase in YY1 binding activity (1.5-fold) when compared to endogenous DNA binding activity for either the C/EBPb or YY1 transcription factors (set as 1), respectively (Figure7A, lower panel). The DNA binding activity for USF2 was not altered following C/EBPb or LAPT235A overexpression (data not shown). These data show that phosphorylation of C/EBPb increases its DNA binding ability and disrupts the YY1 occupancy of its DNA cognition site.
Consequently, we investigated whether this latter effect is mediated by interactions between YY1 and USF2. Co-immunoprecipitation assays demonstrated that NAF treatment does indeed favour the interaction between YY1 and USF2 ( Figure 7B ). As a positive control, immunoblotting was performed using an anti-YY1 antibody. The data presented above suggest that phosphorylation plays an important role in C/EBPb binding to DNA. These findings also demonstrate that the phosphorylation status also influences the DNA binding properties of the YY1 factor and increases the USF2/YY1 interaction.
Discussion
C/EBPb and both related polypetides LAP (liver-enriched activatory protein) and LIP (liver-enriched inhibitory protein) belong to the CCAAT/Enhancer binding proteins (C/EBP) family of transcription factors. These nuclear trans-acting factors play pivotal roles in airway epithelial cell differentiation during lung organogenesis [25] and are involved in the expression of lungspecific and developmentally regulated genes including SP-A and CFTR [5, 6, 7, 8, 26, 27] . We recently identified other trans-acting factors including SRF, YY1, USF2, Sp1 and Nrf2 that contribute to CFTR transcriptional activity [9, 10, 11, 28] . In addition, C/ EBPb has been previously reported to be an important accessory factor for transactivation by several other transcription factors [29] . In an effort to enhance our understanding of the mechanisms that modulate the complex CFTR expression pattern, we investigated the functional role of C/EBPb alongside some previously reported transcription factors.
The data presented in this report show that C/EBPb positively influences CFTR promoter activity in bronchial epithelial cells. Based on knowledge of the CFTR promoter being quite weak, this trans-acting factor may be considered as a strong activator. The results obtained with the C/EBPb-specific siRNA and with mutants for the C/EBPb binding site demonstrate the importance of C/EBPb3 and its binding motif located within a region previously documented to contain two mutations identified in CF patients [11] , [10] . The fact that the CFTR mRNA level was never completely abolished in our assessments is evidence of the C/ EBPb transcription factor controlling CFTR transcription in a coordinated fashion with other partners. We have illustrated here its cooperation with USF2. Moreover, considering the repressor role of YY1 in CFTR transcriptional regulation [9] , we also investigated the putative competition between YY1 and C/EBPb functional activities by transient co-transfection experiments. We demonstrated that the CFTR transcriptional activation elicited by C/EBPb is antagonized by YY1 overexpression. We also showed that this functional antagonism between YY1 and C/EBPb might be partially due to mutually exclusive DNA-binding activities. In addition, although we previously reported that USF cooperates with Sp1 to transactivate the CFTR gene and that YY1 antagonizes SRF, we failed to demonstrate any cooperativity between C/EBPb and either SRF or Sp1 in our promoter context. Indeed, USFs and Sp1 may act as negative regulators when they interact with transcription factors bound simultaneously to the same site or at other sites, suggesting a dual mode of regulation of genes by these factors (28, 29) . Interestingly, the results of this study confirm the complex link between the multiple transcription factors that regulate CFTR transcription.
To further explore the relationship between the C/EBPb, USF2 and YY1 factors, transient co-transfections were performed. Enforced expression of YY1, a powerful repressor, was unable to inhibit CFTR activation induced by USF2. Several concordant results strongly argue in favour of USF contributing towards C/ EBPb-mediated CFTR activation through a functional USF/YY1 interaction. This interaction could at least partially explain the cooperation between C/EBPb and USF2 and the DNA competition observed between C/EBPb and YY1. Based on these data, we propose a model of interaction between USF and YY1 by which USF decreases the inhibitory activity of YY1, either through interacting with the domain mediating the YY1 repressive activity or by impeding access of co-regulators. Indeed, p300 which has been shown to bind YY1, may be essential for YY1 repressor activity [30] . Similar mechanisms have previously been reported for other genes [18, 31] . For instance, USF2 was shown to disturb transcriptional activation by inhibiting the binding of hypoxiainducible factor-1 to the plasminogen activator inhibitor-1 gene in hepatocytes [31] . Another study reported that C/EBPb may alter the DNA binding of activators such as AP-1, by competition and/ or by negatively regulating their transcriptional activity via physical interaction [18] . Thus, more extensive studies including deletions in the protein/protein interaction motifs for USF2 and YY1 factors are envisaged.
In addition to their acquisition of transcriptional activity through selective interactions, transcription factors also require posttranslational modifications in order to function. This highlights the need to study other levels of regulation. Interestingly, it has been shown that C/EBPb is mainly activated by serine/ threonine phosphorylation, which results in its heterodimerization and an increase in its DNA binding [2] . In light of this finding, we assessed whether phosphorylation of C/EBPb has the ability to modulate the CFTR transcriptional activity. By using the Ser/thr phosphatase inhibitor NAF, we demonstrated an increase in C/ EBPb phosphorylation, DNA occupancy and endogenous CFTR expression in bronchial epithelial cells. To confirm these results, we performed transient transfection, RT-qPCR and qChIP assays by using a LAPT235A expression vector, mutated on threonine 235. We found that this mutant protein, unable to be phosphorylated on its Thr residue, could only induce a modest activation of CFTR transcription compared to the increased CFTR expression induced by C/EBPb overexpression and significantly altered the CFTR mRNA level. In addition, the overexpression of the LAPT235A protein induced a considerable decrease in the C/ EBPb DNA binding activity (observed by qChIP analysis) and an increase in the YY1 DNA occupancy. The ChIP analyses were consistent with the results obtained with the NAF treatment. However, other sites of phosphorylation, not studied in our system, might be implicated in C/EBPb activity as was previously reported (13) . These data are in agreement with a recent study showing that phosphorylation of the CREB transcription factor influences CFTR expression [32] . In addition, our findings are particularly interesting since only a low level of CFTR protein is sufficient to allow its normal function [33] . In this manuscript, we also demonstrate that NAF reduces the YY1 DNA binding properties and increases the interaction between YY1 and USF2. These findings strengthen a model by which specific interaction between USF2 and YY1 may result in an increase of both C/ EBPb DNA occupancy and CFTR transcriptional activation (Figure 8 ). This fine balance between negative and positive regulators such as that demonstrated here with the tissue-specific C/EBP factor might explain the finely CFTR regulated expression observed during the development of certain tissues including lung formation [34] .
A crucial point raised is which factors help determine between antagonism and cooperation within a given cell? The answer to this question is very complex and to date not yet elucidated. One important consideration is the expression level of each transcription factor which depends on the specific cell type. For instance, it has been reported that the LIP/LAP ratio may dictate the C/ EBPb transcriptional activity and depend on the cell type [14] . In addition, while most proteins including YY1 and USF are ubiquitously expressed [35, 36] , we must keep in mind that enforced expression of transcription factors may not reflect their real endogenous activities. To gain insight into how such a coordination of gene expression might occur, it will be also instructive to examine posttranslational modifications. Indeed, mounting evidence suggests that acetylation and phosphorylation of nuclear factors may be interdependent [37] . For instance, C/ EBPb recruits p300, triggers massive phosphorylation within its Cterminal domain and thereby modulates p300 activity as a coactivator [38] . Recently, other investigators revealed a cooperation between acetylation and phosphorylation in the control of GATA-1 transcription factor activity [39] . In this regard, an interesting point deserving further attention is the evaluation of both C/EBPb phosphorylation and acetylation status including mutations of the target sites and their impact on C/EBPb DNA binding and protein-protein interaction abilities.
This work has highlighted that such a mode of regulation involving cooperative and antagonistic interaction coupled with posttranslational modification, is an interesting avenue that we will pursue in the future to further unravel the complex regulation of the CFTR gene. 
